# Tyra Biosciences, Inc.: overview TYRA · Nasdaq · CIK 1863127 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tyra.md) · [Financials](/companies/tyra/financials.md) · [Filings](/companies/tyra/filings.md) · [Insiders](/companies/tyra/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.41)](/filings/0001193125-25-266967.md) | not reported | [(0.47)](/filings/0001193125-26-220645.md) | [(0.47)](/filings/0001193125-26-332995.md) | [(0.50)](/filings/0001193125-25-266967.md) | not reported | [(0.64)](/filings/0001193125-26-220645.md) | [(0.69)](/filings/0001193125-26-332995.md) | | Free cash flow | $m | [(18.0) d](/filings/0001193125-25-266967.md) | [(19.6) d](/filings/0001193125-26-085490.md) | [(25.5)](/filings/0001193125-26-220645.md) | [(23.7) d](/filings/0001193125-26-332995.md) | [(22.4) d](/filings/0001193125-25-266967.md) | [(23.7) d](/filings/0001193125-26-085490.md) | [(32.7)](/filings/0001193125-26-220645.md) | [(31.1) d](/filings/0001193125-26-332995.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.91)](/filings/0000950170-23-009181.md) | [(1.32)](/filings/0000950170-24-033461.md) | [(1.62)](/filings/0000950170-25-046124.md) | [(1.51)](/filings/0001193125-26-085490.md) | [(2.01)](/filings/0001193125-26-085490.md) | | Free cash flow | $m | [(24.4)](/filings/0000950170-23-009181.md) | [(50.8)](/filings/0000950170-24-033461.md) | [(50.9)](/filings/0000950170-25-046124.md) | [(70.4)](/filings/0001193125-26-085490.md) | [(95.3)](/filings/0001193125-26-085490.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tyra/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $389.6m | 12,198,625 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $284.9m | 8,920,513 | | Added +1,172,865 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $148.9m | 3,890,589 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $139.2m | 4,352,448 | | Not compared | | [Alta Partners Management Company, L.P.](/funds/2054419.md) | 2026-06-30 | $122.1m | 3,823,425 | | Unchanged | | [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $113.5m | 3,553,585 | | Reduced −502,276 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $103.8m | 3,248,980 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $96.8m | 3,031,972 | | Added +814,043 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $68.4m | 2,140,368 | | Added +924,290 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $59.9m | 1,875,000 | | Reduced −600,000 | ## Recent filings [All 424 filings](/companies/tyra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-17 | 16:32 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000237.md) | Ownership report, active investor, amended | 0001346824-26-000237 | | 2026-09-15 | 19:12 ET | [8-K](/filings/0001193125-26-390951.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-390951 | | 2026-09-09 | 07:10 ET | [8-K](/filings/0001193125-26-385886.md) | 8.01 Other events | 0001193125-26-385886 | | 2026-08-04 | 16:42 ET | [10-Q](/filings/0001193125-26-332995.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332995 | | 2026-08-04 | 16:04 ET | [8-K](/filings/0001193125-26-332752.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332752 | | 2026-06-02 | 16:01 ET | [8-K](/filings/0001193125-26-253435.md) | 5.07 Shareholder vote results | 0001193125-26-253435 | | 2026-05-13 | 08:03 ET | [10-Q](/filings/0001193125-26-220645.md) | Quarterly report, period 2026-03-31 | 0001193125-26-220645 | | 2026-05-13 | 08:00 ET | [8-K](/filings/0001193125-26-220638.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220638 | | 2026-04-17 | 08:08 ET | [DEF 14A](/filings/0001193125-26-160360.md) | Proxy statement, period 2026-05-28 | 0001193125-26-160360 | | 2026-04-17 | 08:02 ET | [8-K](/filings/0001193125-26-160347.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-160347 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-085490.md), filed Mar 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1863127 - Tickers: TYRA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. No prices; not investment advice.